Cancer immunotherapy works by helping the body’s own immune system to destroy cancer cells. Y-mAbs is developing several class leading strategies to guide the immune system for precise tumor killing.
Monoclonal antibodies (mAbs) are engineered natural proteins that can specifically bind tumor targets and recruit host immune system components to destroy the tumor cells.
Naxitamab is our Breakthrough Therapy mAb for the treatment of relapsed/refractory neuroblastoma patients. Naxitamab is a mAb that binds the tumor target GD2, which is abundantly found on neuroblastoma and other related tumors. Naxitamab destroys GD2 expressing cancer cells by antibody- dependent cell mediated cytotoxicity (ADCC) and complement dependent toxicity (CMC). Naxitamab has the highest binding affinity to the GD2 tumor target than any other antibody in clinical development. Naxitamab has been humanized so that it is recognized by the host immune system as self so that the chance of rejection is reduced and efficacy is maximized. Naxitamab is administered by intravenous injection in outpatient clinics.
Y-mAbs is developing a new generation of T cell engaging bispecific antibodies (BsAb) that can destroy tumor cells by recruitment of host T cells in addition to ADCC and CMC. By increasing the armamentarium against cancer cells, the potency of this treatment can be >1000-greater than IgG mAbs. The BiClone format BsAb contains 2 binding arms for the GD2 tumor target and two binding arms for T cells. The BiClone format was designed to have the minimal binding affinity necessary to recruit T cells, while preventing toxicities due to overstimulation seen with other platforms and CAR T therapies.